Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity
A preclinical study in tumor models, not a cancer trial in people.
Cancer Cell, 2016. Di Biase S, et al.
Funding and competing interests (as published with the paper): This study was funded by NIH grant P01 AG034906 to V.D.L. and subcontract HHSN261201200051C from NCI to M.W. R.d.C and A.M.M. were funded by the Intramural Research Program of the National Institute on Aging, NIH. V.D.L. and T.M. have equity interest in L-Nutra, a company developing medical food.
- Study type
- Preclinical study (tumor models)
- Journal
- Cancer Cell
- Published
- 2016
- Authors
- Di Biase S, et al.
- DOI
- 10.1016/j.ccell.2016.06.005
- PubMed ID
- 27411588
Summary
Using preclinical tumor models, researchers tested whether combining chemotherapy with a Fasting Mimicking Diet (FMD) changed how the immune system responded to breast cancer and melanoma tumors.
The authors reported that the combination increased certain immune cell populations (lymphoid progenitor cells and tumor-infiltrating CD8+ T cells) and was associated with delayed tumor progression in the models studied, an effect partly linked to lower levels of a stress-response enzyme (HO-1) in breast tumors.
This is preclinical tumor-model research, not a human cancer trial, and the abstract does not name the species studied beyond 'models.' The findings describe a mechanism observed in these models; this study does not show a cancer-treatment effect in people.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
